Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Telemedicine is increasingly in use during the COVID-19 pandemic.
Results from randomized clinical trials of the antiviral drug continue to show mixed results.
The nation’s health care system provides unrestricted access to hepatitis C treatment.
Researchers analyzed data on more than 80,000 people on the liver transplant list to look for answers.
Researchers found that half of the cases diagnosed through this approach were among people born after 1965.
A recent study of the direct-acting antiviral regimen included people who contracted hep C within the previous 12 months.
Researchers believe that in addition to producing antibodies against the virus, vaccines must also give rise to a cellular immune response.
The specific mode of transmission remains unknown.
Non-alcoholic fatty liver disease can be driven by toxin exposure.
Such risk factors include injecting drugs, being a man who has sex with men and being born in a region with a high prevalence of the virus.
Researchers have challenged findings from a Chinese study that concluded Baraclude is tied to a lower risk of liver cancer.
Researchers are seeking to understand why only 5% of babies born to mothers with hep C become infected.
Non-alcoholic fatty liver disease is more common among those with the virus compared with the general population.
For example, African Americans are more likely to have the virus compared with other races.
Researchers used an insurance database to estimate the hep B diagnosis rate.
A recent Swedish study defined a low-level detectable viral load as between 50 and 999.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.